The rapid increase in size of compound libraries, as well as new targets emerging from the Human Genome Project, require progress in ultra-high-throughput screening (uHTS) systems. In a joint effort with scientists and engineers from the biotech and the pharmaceutical industry, a modular, fully integrated system for miniaturized uHTS was developed. The goal was to achieve high data quality in small assay volumes (1-4 µL) combined with reliable and unattended operation. Two new confocal fluorescence readers have been designed. One of the instruments is a 4-channel confocal fluorescence reader, measuring with 4 objectives in parallel. The fluorescence readout is based on single-molecule detection methods, allowing high sensitivity at low tracer concentrations and delivering an information-rich output. The other instrument is a confocal fluorescence imaging reader, where the images are analyzed in terms of generic patterns and quantified in units of intensity per pixel. Both readers are spanning the application range from assays with isolated targets in homogenous solution or membrane vesiclebased assays (4-channel reader) to cell-based assays (imaging reader). Results from a comprehensive test on these assay types demonstrate the high quality and robustness of this screening system. (Journal of Biomolecular Screening 2003:648-659) Journal of Biomolecular Screening 8(6); 2003 www.sbsonline.org 655 Jäger et al. 658 www.sbsonline.org Journal of Biomolecular Screening 8(6); 2003 FIG. 8. (A) Histogram of Z′ values for the cellular P-glycoprotein pump-inhibitor screen. (B) IC 50 curve of verapamil obtained for this screen, averaged over 7 data points for each inhibitor concentration.
INTRODUCTION
R ECENT DEVELOPMENTS in ultra-high-throughput screening (uHTS) aim at increasing the throughput and decreasing the assay volume to reduce screening costs. For a review summarizing current trends, see the recent study by Wölcke and Ullmann. 1 Miniaturization and increased throughput, however, should be achieved without compromising data quality. Readout techniques based on confocal optics are therefore ideally suited for HTS detection instruments because they enable submicroliter miniaturization without any loss of signal quality. Furthermore, single-molecule detection (SMD) methods can be employed on confocal readers generating data with a high degree of information. [2] [3] [4] [5] [6] [7] [8] [9] Advantages and limitations of SMD techniques for HTS have been discussed in earlier work. 10 At that time, this technology suffered from low throughput, insufficient robustness, and unavailability of decent HTS equipment. Therefore, a lot of effort was put in improving SMD-enhanced HTS technology with the first integrated systems gradually becoming available (e.g., from Evotec Technologies, ZEISS, Aurora). One of the early instruments, the EVOscreen™ Mark-II system (Evotec Technologies), allows running assays in volumes of 1 microliter in the 2080-well plate format. It employs piezoelectric pipettes and dispensers as liquid handling devices and confocal microscopes equipped with 1 objective per reader ("single-channel reader") for detection. The throughput of this system is limited by the well-by-well readout process; with typical readout times as required for SMD methods, it is around 50,000 wells/24 h.
The principle goal that has guided the design of the next-generation screening platform as presented here is to provide higher throughput (>100,000 wells/24 h), increased operational flexibility (1536-well SBS standard plate format, integration of 3rd-party devices), and improved reliability (automated quality control, error handling) compared with its predecessor, Mark-II. To achieve the required throughput for the complete set of Evotec's FCS+plus detection methods, a new reader was designed (as already an-nounced in Moore and others 10 ). This reader combines the optical elements of 4 confocal microscopes into 1 instrument (4-channel reader) being able to measure 4 wells within a plate in parallel with 4 objectives, resulting in a 3-to 4-fold improvement of throughput compared with a single-channel reader. To achieve equal dispensing speed and balanced throughput of the overall system, double piezo dispensing stations were designed, and an 8-channel synQUAD™ dispenser (Cartesian Technologies) was integrated for bulk dispensing of reagents or cell suspensions. A new online quality control for the piezo dispensers automatically detects and removes malfunctions (e.g., bubbles) and hence enables a reliable dispensing process.
For the data acquisition of cellular applications, a confocal imaging reader was developed. This reader is able to record and analyze confocal fluorescence images from cells, beads, or any other objects in the sample.
Data quality and stability of the new screening system (EVOscreen™ Mark-III) are demonstrated in tests of the separate modules as well as extended screening runs involving all integrated modules. The single module tests stressed the precision of the reformatting and dispensing processes, while the extended screening runs focused on the overall performance of the complete system. Four different assays were screened during the testing campaign, covering the following biological targets: protein-peptide binding, ribosome-antibiotic interaction, membrane receptorligand binding and P-gp (P-glycoprotein) pump-inhibitor interaction. The last 2 assays were designed as vesicle-based and cellbased assays, respectively. A steady-state throughput of >100,000 wells/24 h was achieved for all 4 assays, and the respective mean Z′ values were determined to be 0.76, 0.90, 0.60, and 0.56.
MATERIAL AND METHODS

Reagents
The reagents for the protein-peptide binding assay as well as for the ribosome-antibiotic assay were prepared in house at GlaxoSmithKline.
β2 ligand CGP 12177A was purchased from RBI (Natick, MA). CMFDA (5-chloromethylfluorescein diacetate), Ethidium Homodimer, and calcein acetoxymethyl ester (CaAM) were from Molecular Probes Europe (Leiden, the Netherlands). Verapamil was from Sigma (Taufkirchen, Germany).
Cell lines and membrane preparations
U937 cells were used for the live/dead assay, and MES-SA/Dx5 cells overproducing P-glycoprotein were used for the P-glycoprotein assay. For the membrane vesicle assay, the β2 adrenergic receptor was chosen. Wild-type human β2 adrenergic receptor cDNA was cloned into the plasmid pcDNA3. The plasmid was transfected into HEK293 cells, and stable clones were selected as described in Gabilondo et al. 11 The membrane preparations were made according to Scheel et al. 12 
Screening equipment
Reformatting system (Mitona)
The Mitona (micro to nano) module is a fully automated reformatting system that is able to handle different plate types. This feature is addressed by retooling the relevant tables and grippers and can be done in a few minutes. Formatting from standard 96-or 384-well microplates (e.g., Greiner, Costar, Nunc) into 1536-or 2080-well nano-plates (NanoCarriers, Evotec Technologies) as well as into standard 1536-well sample carriers (e.g., Nunc, MMI) is possible. For the reformatting process, 2 independent pipetting stations (table A and B, equipped with 8 pipettes each) are available. The Mitona pipettes are based on piezo-driven micropump technology, which allows the transfer of compound volumes down to 5 nl with high accuracy (≤10% coefficient of variation [CV]). The pipettes are equipped with a level detection system, which contributes to compound saving. The dispensing tables are temperature controlled to reduce evaporation and temperature effects on the compounds. A screening run can be performed either in the "wet compound" mode, where the reformatting process is performed shortly before filling the NanoCarrier with assay reagents, or in the "storage compound" mode, where compound solutions are dried in the NanoCarrier by 2 evaporator units. The evaporator units ensure a controlled and reproducible drying of the compounds by applying low pressure, high gas flow, and additional heating. Drying down compounds has the advantage that reformatting and assay processing are uncoupled, which allows compound handling and screening to be performed at different sites. On the other hand, care has to be taken for proper and reproducible resolubilization of the compound. Therefore, in the storage compound mode, the sample carrier has to be precoated with an appropriate excipient. In the data presented in this article, the Mitona was used in the wet compound mode.
Dispensing systems
Scarina dispensing stations
The Scarina (Screening and reading in nanoscale) dispensing module is equipped with 4 dispensing stations (tables), each consisting of 2 assay and 2 rinse reservoirs, serving 2 pairs of micropumps (1 pair designed as backup). In the double dispensing mode, which allows for dispensing 1 assay solution with 2 micropumps in parallel, a total of 8 micropumps can be used at the same time. Because each of the dispensing stations includes 2 assay reservoirs, a total of 8 different assay solutions can be used per screen.
The micropumps are based on piezo technology and allow nanoliter volume resolution. Each of the 32 micropumps is quality controlled by a newly developed dispenser control box, which is able to monitor their performance online. In brief, the central unit of the micropump embodies a piezo element, which, on applying an appropriate voltage at a certain frequency, will drive the pumping process. The quality of the emerging nano droplets is evaluated Confocal Fluorescence Analysis Techniques by digital signal processing units in the control box. If a decrease of performance is detected, the dispensing process is interrupted, and appropriate rinsing procedures are started until the desired performance is reached again. For standard assay solutions of soluble components, this is a rare event, but in the case of nonhomogenous suspensions, for example, vesicle-based assays, about 0 to 3 times rinsing (for a few seconds) is performed per NanoCarrier. This quality-control mechanism ensures that the dispensing quality still remains excellent, even in the nanoliter range (as required when using Evotec 2080 plates with 1-µL total assay volume). The additional use of filters in the tubing at the inlet of the piezo-micropumps helps to prevent their blockage. All above-mentioned features add to the performance and reliability of an unattended screening run.
Here the Scarina dispensing stations were used to dispense dye, buffer, labeled ligand, inhibitor, and protein. The dead volume of each micropump was determined to be around 40 µL.
The synQUAD™ dispenser
This device from Cartesian Technologies is able to dispense volumes from 50 nL to 8 µL with 8 different dispensers into 96-, 384-, and 1536-well microplates. A syringe pump displaces a quantitative amount of fluid, which is controlled by a microsolenoid valve (proprietary technology of Cartesian Technologies). Parallel dispensing is achieved by synchronizing dispenser solenoids and stepper motors, which control syringe and plate movements.
Here the synQUAD™ dispenser was used to dispense high volumes (2-3 µL) into 1536 sample carriers, using a 5-mL syringe. For cellular applications, the syringe was modified by Evotec such that a homogenous distribution of the cells is obtained. A temperature control and CO 2 supply for the reservoir was installed as well. The dead volume of the synQUAD™ dispenser was around 2 mL.
Readout systems
The Mark-III system holds 2 "plug-and-play" docking interfaces for readers. Currently, 5 different types of fluorescence readers can be installed, and 2 readers can be used in parallel.
The 4-channel FCS+plus reader
This fluorescence reader is able to measure one 1536-well plate using 4 objectives in parallel, thus enhancing the readout time by 3to 4-fold compared with Evotec's single-channel reader, as previously used on the Mark-II platform. The optical setup comprises 4 independent confocal alignments, serving 1 objective each and allowing for 2 detection channels per objective to measure, for example, 2 polarization directions. Hence, in this mode, 8 independent single photon counting modules record the fluorescence signal from 4 different wells of a 1536 NanoCarrier at the same time. Instead of the 2 polarization directions, 2 different colors can be monitored. The reader is equipped with 3 different solid state lasers, 1 optically pumped semiconductor laser system (488 nm, 20 mW), 1 Nd:YAG laser system (532 nm, 50 mW), and 4 laser diode modules (638 nm, 5 mW each). Appropriate filter sets separate excitation and emission wavelength, block Raman scattering, and suppress unwanted cross-talk (if a 2-color application is chosen).
The following statistical methods ("photon statistics") can be applied to convert the primary fluorescence signal into output data, which can be related to properties of the sample:
FCS (Fluorescence Correlation Spectroscopy). This technique is able to monitor single molecules by recording the intensity autocorrelation function of fluorescent molecules in a microscopic small volume. [2] [3] [4] [5] In brief, to obtain the autocorrelation function, the product of the fluorescent intensity at different delay (correlation) times is taken and averaged over the measurement time. As the intensity varies with the number of fluorescent molecules diffusing into and out of the confocal volume (of approximately one femtoliter), FCS provides a measure of the molecular motion. The fitting parameters are the translational diffusion time(s) and the number (concentration) of the molecule species.
FIDA (Fluorescence Intensity Distribution Analysis) and 2D-FIDA (2-Dimensional-Fluorescence Intensity Distribution
Analysis). Instead of recording the temporal fluctuation of a fluorescence signal (as in FCS), FIDA relies on the amplitude fluctuations and hence analyses the statistics of the number of photons counted, typically collected in time windows of 40 µs duration. 6, 13, 14 As a result, a photon count histogram can be built and compared with the theory. This theoretical model takes into account the double-Poissonian nature of the signal (both the number of dye molecules in a volume element and the number of photons emitted by a given number of dye molecules exhibit a Poissonian distribution), as well as the inhomogeneous illumination profile within the confocal volume. The fitting parameters are concentration and molecular brightness of the different molecular species. The latter parameter is expressed as number of photons per second (in Hertz). The ability to detect concentrations of several components, based on their different brightness values, makes a wide range of assay formats accessible and allows separation of the assay signal from interfering effects (e.g., autofluorescence of test compounds). 7, 9 The concentrations of molecular species determined by FIDA (e.g., free versus bound ligand) can be used to calculate fractional binding. 15 In 2D-FIDA, 2 detectors monitor the fluorescence intensity of either different wavelengths or different directions of polarization. The main advantage of this method is the coincident information of 2 detectors, which allows additional detection modes, improves the statistics, and hence makes shorter measurement times possible. In addition, more complex assay systems become possible. 8, 16 Here, fluorescence anisotropy-based 2D-FIDA (FA-2D-FIDA) and 1D-FIDA were chosen as analysis methods for the 3 isolated target assays.
The Opera (confocal imaging reader)
The Opera (Evotec Technologies) generates confocal fluorescence images from objects such as beads or cells in suspension or sedimented on the well bottom of different sample carries (e.g., 96, 384, or 1536 carrier). Instead of 1 laser beam, approximately 1000 laser beams are created by a set of pinholes on a rotating disc, which scan the sample simultaneously (Nipkow disc design; see, e.g., Kino 17 ). During 1 s, several hundred complete scans of the focus plane in the sample are taken and integrated by a CCD camera. Depending on the application, the thickness of the optical section of the sample can be chosen from 1 to 10 microns, and the lateral resolution can be varied in the range of about 0.3 to 3 µm. The images are analyzed by extracting parameters such as object pattern, object size, brightness, and so on. Two different excitation wavelengths (out of 3 currently available wavelengths, 488 nm, 532 nm, and 632 nm) can be chosen, and hence 2 images can be recorded at the same time by the 2 CCD cameras. Also, on both cameras, several exposures with different excitation or detection wavelengths can be recorded, increasing the number of data channels. This allows monitoring of several reactions simultaneously, for example, the viability of cells concurrent with the biological reaction of interest. Here, the Opera was used both in the 2-color and in the 1color mode.
The Acquest™ reader
The Acquest™ Ultra-HTS Assay Detection System (Molecular Devices) is designed for 96-, 384-, and 1536-well microplate formats and can read in 6 different modes: fluorescence intensity, fluorescence anisotropy, time-resolved fluorescence, luminescence, absorbance, and epi-absorbance.
Here, the Acquest™ reader was used in the fluorescence intensity mode to read Nunc™ 1536 microplates. Recently, 2 more readers, the Analyst GT (Molecular Devices) and the Zeiss Plate: Vision, were integrated as well.
RESULTS AND DISCUSSION
To test the complete Mark-III system, a number of different experiments have been performed. Mitona and Scarina dispensing was addressed by single-module tests, whereas 4 complete biological screens validated the overall performance of the uHTS system.
Single-module test: Mitona cross-contamination
In this test, the well-to-well carryover, caused by the Mitona reformatting step, was determined. A 384-well microplate was spiked at every 8th position (6 spiked wells for each of the 8 Mitona pipettes) with 100 µM TAMRA (tetramethylrhodamine diluted in 70% DMSO). All other wells were filled with 70% DMSO. Of each well, 30 nL was reformatted by the Mitona into a 1536-well NanoCarrier and subsequently filled with buffer (3 µL phosphate buffered saline [PBS] with 0.1% Pluronic F127). Pluronic F127 was used in all buffers to prevent molecule adsorption (here, TAMRA) to the well surface. The carryover into the 6 wells adjacent to the spiked well was measured by a fluorescence reader and compared to hand-pipetted controls, which served as calibration. As a result, the cross-contamination in the direct neighboring well was determined to be below 0.015%, decreasing continuously for all following wells. Similar results were obtained for the second pipetting table.
Single-module test: Mitona precision
For testing the precision of the Mitona micropumps, volumes of 10, 30, 50, and 100 nL of a 3-µM TAMRA solution (diluted in 70% DMSO) were pipetted from 384-well microplates (for each volume, one 384-well microplate was used) into 1536-well NanoCarriers. Subsequently, the NanoCarriers were filled with buffer, and the total intensity was measured ( Fig. 1A) and averaged for each volume (Fig. 1B) . The regression resulted in a linearity of r 2 = 0.99, and the precision (CV values) of all 8 piezo pipettes aver- 
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aged over 384 wells was determined to be 3.0% ± 1.7%, 3.3% ± 2.3%, 3.7% ± 2.5%, 5.3% ± 3.0% for the volumes 100, 50, 30, and 10 nL, respectively. Hand-pipetted standards with a calibrated Eppendorf pipette confirmed that the absolute volumes were pipetted within a maximum deviation of 10%. Similar results were obtained for the second pipetting table.
Single-module test: precision of Scarina micropumps
Here the precision of all 32 piezo micropumps from the Scarina dispensing module was measured, using the double dispensing mode. Of a 5-nM TAMRA solution, 1.5 µL (diluted in PBS with 0.1% Pluronic F127) was dispensed into 1536 NanoCarriers. Buffer was added to a final volume of 3 µL by the synQUAD™. The layout of the run was designed to test 8 different micropumps within 1 carrier, resulting in 4 NanoCarriers to test all 32 pumps. The precision run was repeated 3 times with identical performance (all in all 12 carriers). The average CV across plates was determined to be 5.5% ± 0.9% (minimum 3.8%, maximum 7.1%), and the average CV for micropumps was 4.4% ± 1.2% (minimum 3.1%, maximum 9.9%) (data not shown).
Single-module test: 4-channel FCS+plus reader
Two different optical alignments can be chosen: FCS optic and FIDA optic. For testing the FCS optic, 12 NanoCarriers were filled with TAMRA solution (2 nM diluted in PBS + 0.1% Pluronic F127), and the diffusion time of TAMRA was determined in each well with a read time of 1 s per well. The average of all 1536 wells from 1 NanoCarrier was calculated and then again averaged over all 12 NanoCarriers. This resulted in mean values and variations as summarized in Table 1 .
The CV values of all 4 channels are comparable and below 10%, demonstrating a balanced performance within the channels. A similar experiment was performed using the FIDA optic setup. The molecular brightness of TAMRA was determined in each well by measuring 1 s per well. Again, the CV values within and across plates were below 10% for all detection channels.
Screening run: dye test run
The dye test run was designed to test the quality and reliability of reformatting with the Mitona module. Of a 3-µM TAMRA solution, 30 nL (in 70% DMSO) was reformatted into Nunc™ 1536 microplates and filled with 5.4-µL PBS (including 0.2% Pluronic F127) by the synQUAD™. Control wells (10 nM TAMRA) were dispensed by the piezo micropumps of the Scarina, and the plates were subsequently measured by the Acquest™. The average CV value from 44 microplates (screened within 13 h, 18 min) was measured to be 5.9%, with values ranging from 4.2% to 9.3%. A steady-state throughput, which was calculated from the time elapsed from the first to the last measured well, being equivalent to 122,000 wells per 24 h, was achieved. The determined miss rate was as low as 0.03% (defining 25% of the expected count rate as threshold), or 0.15% (defining 50% of the expected count rate as threshold), or 0.33% (defining 75% of the expected count rate as threshold). The steady-state throughput calculation here and in the following resulted from extrapolation because usually not more than 2 working shifts were performed per day.
Biochemical screening runs
Typical biochemical screening runs on the Mark-III system such as the test runs described below follow this general scheme: After reformatting compounds from 384-well source plates into 1536-well screening plates, buffer, labeled ligand, and protein, as well as dye and inhibitor for the control wells, were added. Subsequently, the screening plates were incubated at an appropriate temperature/humidity before they were read on the 4-channel reader. The raw data were automatically transferred to a separate computer used as a fit machine, fitted to an appropriate model and then stored in a database. An export of the analyzed data from the database (e.g., into a Microsoft Excel template) finalized the evaluation process.
Three different cell-free assays were screened within 9 working days, summing up to a total of 352 NanoCarriers. In total, it took 111 h and 15 min to screen all 540,672 wells, referring to an average steady-state throughput of 116,000 wells per 24 h.
In all screening runs, 30 nL compound was reformatted by the Mitona from 384-well microplates into 1536-well NanoCarriers shortly before the assay components were added (usually within 1 h). Reformatting was not rate limiting. As the readout method FA-2D-FIDA could be applied to all 3 assays, whereas the vesicle assay, in addition, was analyzed by 1D-FIDA according to Schaertl et al. 15 The measurement time was kept at 1 s per well for all screens (including polarization, where both polarization direc- tions were measured in parallel), which reflected the rate-limiting step. All Scarina and Mitona tables were kept at 15°C to minimize evaporation.
Screening run: protein-peptide assay
The upper-right panel of Figure 2 shows a typical screening layout, as used for the soluble assays.
Due to the 4-channel reader geometry, which measures with 4 objectives in parallel and hence is equivalent to 4 independent readers, the 1536 NanoCarrier was divided into 4 fitzones (quadrants) representing 1 objective each (A, B, C, D). For the control wells, 4 dye (green), 12 high-control (red), 8 low-control (blue), 6 conjugate (ligand only) (pink), and 2 background wells (white) were reserved per fitzone. In addition, the plates were spiked with 8 IC 50 curves of 1 inhibitor (area D of Fig. 2 , upper-left panel, rising concentrations from red to blue) and with the 10-fold IC 50 of a different inhibitor (16 sets of 4 adjacent wells in areas A and C).
The 1st screen reflects a simple protein-peptide binding assay. A Rhodamine Green-labeled peptide (excitation at 488 nm) binds to a soluble protein in a one-to-one ratio with a K D of 5 nM (Hutchinson et al., unpublished data). After reformatting compounds, 2.7 µL buffer was dispensed by the synQUAD™ and 200 nL protein as well as 200 nL conjugate (labeled peptide) solution were dispensed by the piezo micropumps. The final assay concentrations for protein and conjugate were 12 and 1.3 nM, respectively. In the low-control wells, competitor (10-fold IC 50 ) was added, followed by a 1-h incubation at 22°C. Subsequently, the plate was measured by the 4-channel reader, employing FA-2D-FIDA as the readout method. The fraction bound was calculated according to Schaertl et al. 15 Within 1 week (5 working days), 176 plates were screened (270,336 wells). An average steady-state throughput being equivalent to 118,000/24 h was achieved. The setup time of the complete screening system for 2 users was 66 min per day on average. As few as 2 user interventions (defined as interruption, which cannot be resolved by an automated procedure) during the 64 h of operation occurred and could be solved within a few minutes (not counting refilling of assay reagents). Otherwise, the screening run was performed unattended. Figure 3 shows the Z′ values calculated according to Zhang et al., 18 which reflect the quality of the data.
For 91% of all fitzones, Z′ was greater than 0.6, which was defined as the rescreening threshold. The average Z′ was 0.76, and the median was 0.81. To test the accuracy of compound reformatting and assay dispensing, the compound wells were spiked as shown in Figure 2 (upper-left panel area D) . The resulting inhibition is plotted in 2D as well as 3D format in the bottom panels. A dose-response fit of the averaged data is shown in Figure 4B together with data from 3 consecutive NanoCarriers of the same compound, as well as a different compound (Fig. 4A) , obtained analogously. The average IC 50 values were determined to be 74 ± 11 nM (compound A) or 192 ± 14 nM (compound B). Similar IC 50 values were measured previously (Hutchinson et al., unpublished data). The deviation of IC 50 values across the run was between 10% and 15%, demonstrating high data quality under the conditions of a primary uHTS screen. In addition to the dose-response curves, the plates were spiked with the 10-fold IC 50 concentration of a different inhibitor (Fig. 2 , upper-left panel, 16 sets of 4 adjacent wells in areas A and C). The number of misses (defined as anisotropy >0.08, high control = 0.146 ± 0.014, low control = 0.026 ± 0.008) due to reformatting errors by the Mitona was determined to be 0.45%, and the overall miss rate (including Scarina performance, e.g., failures in dispensing conjugate, measuring, fitting, etc.) amounted to 0.57%.
Screening run: ribosome-antibiotic assay
In this experiment, a Cy3B-labeled antibiotic (excitation at 532 nm) binds to ribosomes in a one-to-one ratio. 19 For the ribosome preparation used here, a K D of 38 nM was found (data not shown). The assay was performed in a similar manner to the protein-peptide binding assay; however, the ribosome solution (2.7 µL per well) was dispensed by the synQUAD™, and the incubation time was set to 2 h at 22°C. Final assay concentrations for ribosomes and conjugate were 76 nM and 2 nM, respectively. Again, the plates were measured using the 4-channel reader, employing FA-2D-FIDA as readout.
Within 2 days, 88 plates were screened (135,168 wells). Average steady-state throughput, setup time, user interventions, and miss rate are summarized in Table 2 . Figure 5A represents the histogram of Z′ values (average Z′ = 0.9, median Z′ = 0.97), demonstrating both a robust assay as well as a robust machine performance.
Once more, the compound wells were spiked with known inhibitors of the binding reaction. Some typical examples of the resulting IC 50 curves are shown in Figure 5B for 4 selected compounds with different potencies. The resulting IC 50 values were determined to be 111 ± 4, 161 ± 5, 249 ± 14, and 595 ± 42 nM. Using the fluorescence anisotropy format of this assay, 19 the same order of potencies and, within the experimental errors, the same IC 50 values have been found for these compounds (Bingham et al., unpublished data).
Screening run: membrane receptor-ligand assay
This screening run was intended to verify the capability of the Mark-III system to screen with vesicle-based assays. The assay was configured by preparing vesicles from cells containing the β2 adrenergic receptor and using a Rhodamine Green-labeled ligand (CGP 12177A) with final assay concentrations of 190 µg/ml receptor and 1 nM ligand. Binding of ligands to vesicles (K D = 1.4 nM) results in bright particles allowing quantification of bound and unbound ligand by 1D-FIDA. 12, 20 The calculated molecular intensities were determined to be in the range of 20 to 30 kHz for the labeled ligand and 400 to 600 kHz for the vesicles, reflecting an approximate binding stoichiometry of 20 ligands per membrane vesicle (data not shown). In addition, the data were analyzed by FA-2D-FIDA.
In total, 135,168 wells (88 plates) were screened within 2 days with a performance summarized in Table 2 . Choosing 1D-FIDA or FA-2D-FIDA as the analysis method, Z′ values were obtained as shown in Figure 6A or 6B, respectively. In both cases, the average and median Z′ value was 0.60 and 0.64, respectively. However, the 1D-FIDA analysis was able to discriminate between free and bound ligand in 9 fitzones (Z′ > 0.4) where the anisotropy (FA-2D-FIDA) analysis failed (Z′ < 0.4); vice versa, 6 fitzones were fit better by anisotropy (again applying the Z′ criteria limit of 0.4). As a consequence, the rescreen rate dropped from 3.0% in 1D-FIDA (or 3.9% in FA-2D-FIDA) down to 1.0%, taking both analysis methods into account. This demonstrates the advantage of multiple readouts being applied at the same time.
Single-module test: live-dead assay
In this single-module test, the cell-dispensing performance of the modified synQUAD™ was addressed by employing a livedead assay. CMFDA (5-chloromethylfluorescein diacetate) prestained cells (green cells = live cells) were dispensed into 1536 NanoCarriers, which were preloaded with ethidium homodimer. If the cells die, ethidium homodimer diffuses through the cell membrane, giving rise to a red cell fluorescence (dead cells). Figure 7 shows a typical example of the resulting cell image detected by the Opera. The number of dead cells (colored red and green) can easily be discriminated from the live cells (colored green) and was determined to be 8.7% ± 1.3%, calculated from 32 plates. The handpipetted controls resulted in 13.3% ± 3.0% dead cells, determined from 12 plates (data not shown). This demonstrates that the dispensing process has no significant effect on cell viability; in contrast, automated dispensing is advantageous.
Screening run: P-glycoprotein pump-inhibitor assay
The last uHTS run was designed to test the performance of the Mark-III system with respect to cell dispensing, cell image acquisition, and subsequent cell image analysis by the Opera. In this assay, the nonfluorescent calcein acetoxymethyl ester (CaAM) passively diffuses through the cell membrane of a multidrug resistance (MDR) cell containing the P-glycoprotein (P-gp) pump. Upon active transport, the ligand is extruded from the cell (low control). Adding a P-gp inhibitor (e.g., verapamil) results in an accumulation of CaAM in the cytoplasm where it is hydrolyzed by intracellular esterases yielding fluorescent calcein (high control). The layout of the cellular screen was similar to the soluble screens; however, the control wells were restricted to high and low controls only.
After reformatting compounds into 1536 NanoCarriers, 50 nL verapamil (assay concentration 40 µM) was dispensed into the high-control wells. Subsequently, 2 µL of calcein AM (250 nM) and 2 µL of suspended MDR cells (2800/well) containing the P-gp pump were dispensed into all wells by the modified synQUAD™. A 3-h incubation at 37°C and 90% humidity followed before the plate was measured and analyzed by the Opera. The analysis and quantification was based on identifying the cells and determining Table 2 , and the histogram of Z′ values is presented in Figure 8A . Average and median Z′ values were determined to be 0.56 and 0.58, respectively.
As in the biochemical screens, the NanoCarriers were spiked with IC 50 s, resulting in a titration curve as shown in Figure 8B . The IC 50 value was determined to be 3.0 ± 0.4 µM, compared to 7.2 ± 2.2 µM published in Tiberghien et al. 21 
STRENGTHS AND LIMITATIONS OF THE MARK-III SYSTEM
The strengths of the presented system are low assay volumes (typically 1-3 µL for soluble and 4 µL for cellular applications); information-rich data output (such as individual molecular brightness, anisotropy, diffusion time); high data quality (2 examples: only 10%-15% IC 50 variation under primary screening conditions and reducing rescreen rate from 3% to 1%, when 2 readouts are applied simultaneously); integrating devices from other suppliers, such as dispensing stations or readers (which was realized by designing 3 plug-and-play interfaces being able to integrate a synQUAD™ dispenser and 2 readers); online quality control of all piezo dispensers (which guarantees a robust dispensing performance); and assay development and screening performed on simi- 
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FIG. 7.
Live-dead assay performed on the Mark-III system using the modified synQUAD™. Green cells refer to live and red and green cells to dead cells, respectively. The image was recorded and analyzed by the Opera.
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lar equipment (because the respective benchtop instruments work with the same plates, fluidics, and readouts).
On the other hand, the Mark-III system bears its limitations. Although many forms of light-based readouts can be applied (fluo-rescence, absorbance), this system cannot handle radioactivity. Furthermore, if fluorescence fluctuation techniques are used, the application of the fluorophore concentration is limited to less than 50 nM. The usage of low volumes and concentration also makes a special adaptation phase during the assay development necessary, due to, for example, an increasing surface-to-volume ratio of the sample carrier. Compound libraries often suffer from impurities and/or autofluorescence. Although algorithms have been developed to correct for autofluorescence, impurities that have a quenching effect on the fluorophore cannot be accounted for. 9
SUMMARY AND CONCLUSION
The need for the development of new screening technology initiated a collaboration between the biotech and the pharmaceutical industry. A major goal was to extend the commercially available screening systems by a new development that takes advantage of confocal fluorescence readout techniques, the resulting data being amenable to photon statistics. Inherent to these techniques is the information-rich data output and the miniaturization benefit, both of which were realized within the presented screening system. With this system, miniaturized screens for a wide range of assay formats can be performed, ranging from isolated target assays with soluble proteins or membrane vesicle suspensions to cell-based applications. Table 2 summarizes the results from the described testing campaign with regard to instrumental assay performance. On average, only one user intervention per day was necessary; otherwise, the screening runs were performed in a fully automated fashion except for reagent refilling.
